dc.contributor
Institut Català de la Salut
dc.contributor
Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERDEM (ISCIII), Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Biagetti Biagetti, Betina
dc.contributor.author
Simó Canonge, Rafael
dc.date.accessioned
2025-10-25T08:54:54Z
dc.date.available
2025-10-25T08:54:54Z
dc.date.issued
2022-06-14T07:33:46Z
dc.date.issued
2022-06-14T07:33:46Z
dc.date.issued
2021-01-02
dc.identifier
Biagetti B, Simó R. GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice. Int J Mol Sci. 2021 Jan 2;22(1):415.
dc.identifier
https://hdl.handle.net/11351/7677
dc.identifier
10.3390/ijms22010415
dc.identifier
000606291500001
dc.identifier.uri
http://hdl.handle.net/11351/7677
dc.description.abstract
Acromegaly; Growth hormone; Myopathy
dc.description.abstract
Acromegalia; Hormona de crecimiento; Miopatía
dc.description.abstract
Acromegàlia; Hormona del creixement; Miopatia
dc.description.abstract
The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field.
dc.format
application/pdf
dc.relation
International Journal of Molecular Sciences;22(1)
dc.relation
https://doi.org/10.3390/ijms22010415
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Músculs - Malalties
dc.subject
DISEASES::Musculoskeletal Diseases::Muscular Diseases
dc.subject
Other subheadings::Other subheadings::Other subheadings::/metabolism
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Somatomedins::Insulin-Like Growth Factor I
dc.subject
Other subheadings::Other subheadings::Other subheadings::Other subheadings::/deficiency
dc.subject
ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculares
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/metabolismo
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::somatomedinas::factor I de crecimiento insulinoide
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::Otros calificadores::/deficiencia
dc.title
GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
